Indazole compounds
AssigneeAsahi Kasei Pharma Corporation
InventorsSeiji Nakano, Taisuke Iwanami, Kei Yamanishi, Yasuhiro Wada, Akifumi Morimoto
Life of this patent
Estimating the term…
Abstract
Provided are compounds represented by the following formula (A-1) and formula (1), or salts thereof. The compounds of formula (A-1) and formula (1) or salts thereof have β3 adrenergic receptor agonist activity, and thus are useful as therapeutic and prophylactic agent for diabetes mellitus, obesity, hyperlipidemia, depression, diseases caused by gallstones or hypermotility of the biliary tract, diseases caused by hyperactivity of the digestive tract, interstitial cystitis, overactive bladder or urinary incontinence, or as therapeutic and prophylactic agents for diseases concomitant with decreased tears.
Claims15
A compound selected from the group consisting of the following:
- (R)-N-(3-(2-(2-(3-ethylindazol-6-yloxy)ethylamino)-1-hydroxyethyl)phenyl)methanesulfonamide;
- (R)-N-(3-(2-(2-(3-n-propylindazol-6-yloxy)ethylamino)-1-hydroxyethyl)phenyl)methanesulfonamide;
- (R)-N-(3-(2-(2-(3-isopropylindazol-6-yloxy)ethylamino)-1-hydroxyethyl)phenyl)methanesulfonamide;
- (R)-N-(3-(2-(2-(3-trifluoromethylindazol-6-yloxy)ethylamino)-1-hydroxyethyl)phenyl)methanesulfonamide;
- (R)-N-(3-(2-(2-(3-methoxymethylindazol-6-yloxy)ethylamino)-1-hydroxyethyl)phenyl)methanesulfonamide;
- (R)-3-(6-(2-(2-hydroxy-2-(3-methylsulfonamido)phenyl)ethylamino)ethoxy)indazol-3-yl)-N,N-dimethylpropanamide;
- (R)-N-(2-chloro-5-(1-hydroxy-2-(2-(3-isopropylindazol-6-yloxy)ethylamino)ethyl)phenyl)methanesulfonamide;
- (R)-N-(5-(2-(2-(3-ethylindazol-6-yloxy)ethylamino)-1-hydroxyethyl)-2-fluorophenyl)methanesulfonamide;
- (R)-N-(2-chloro-5-(2-(2-(3-ethylindazol-6-yloxy)ethylamino)-1-hydroxyethyl)phenyl)methanesulfonamide;
- (R)-N-(2-fluoro-5-(1-hydroxy-2-(2-(3-(trifluoromethyl)indazol-6-yloxy)ethylamino)ethyl)phenyl)methanesulfonamide;
- (R)-N-(2-chloro-5-(1-hydroxy-2-(2-(3-(trifluoromethyl)indazol-6-yloxy)ethylamino)ethyl)phenyl)methanesulfonamide;
- (R)-N-(3-(1-hydroxy-2-(2-(3-methylindazol-6-yloxy)ethylamino)ethyl)phenyl)propane-2-sulfonamide;
- (R)-N-(3-(2-(2-(3-ethylindazol-6-yloxy)ethylamino)-1-hydroxyethyl)phenyl)propane-2-sulfonamide;
- (R)-N-(3-(1-hydroxy-2-(2-(3-methylindazol-6-yloxy)ethylamino)ethyl)phenyl)benzenesulfonamide;
- (R)-N-(3-(2-(2-(3-ethylindazol-6-yloxy)ethylamino)-1-hydroxyethyl)phenyl)benzenesulfonamide;
- (R)-N-(3-(1-hydroxy-2-(2-(3-methoxyindazol-6-yloxy)ethylamino)ethyl)phenyl)benzenesulfonamide;
- and
- (R)-N-(3-(2-(2-(3-ethylindazol-6-yloxy)ethylamino)-1-hydroxyethyl)phenyl)ethanesulfonamide,
- or a salt thereof.
A compound selected from the group consisting of the following:
- (R)-N-(3-(2-(2-(3-ethylindazol-6-yloxy)ethylamino)-1-hydroxyethyl)phenyl)methanesulfonamide;
- (R)-N-(3-(2-(2-(3-n-propylindazol-6-yloxy)ethylamino)-1-hydroxyethyl)phenyl)methanesulfonamide;
- (R)-N-(3-(2-(2-(3-isopropylindazol-6-yloxy)ethylarnino)-1-hydroxyethyl)phenyl)methanesulfonamide;
- (R)-N-(3-(2-(2-(3-trifluoromethylindazol-6-yloxy)ethylamino)-1-hydroxyethyl)phenyl)methanesulfonamide;
- (R)-N-(3-(2-(2-(3-methoxymethylindazol-6-yloxy)ethylamino)-1-hydroxyethyl)phenyl)methanesulfonamide;
- (R)-3-(6-(2-(2-hydroxy-2-(3-(methylsulfonamido)phenyl)ethylamino)ethoxy)-indazol-3-yl)-N,N-dimethylpropanamide;
- (R)-N-(5-(2-(2-(3-ethylindazol-6-yloxy)ethylamino)-1-hydroxyethyl)-2-fluorophenyl)methanesulfonamide;
- (R)-N-(2-chloro-5-(2-(2-(3-ethylindazol-6-yloxy)ethylamino)-1-hydroxyethyl)phenyl)methanesulfonamide;
- (R)-N-(2-chloro-5-(1-hydroxy-2-(2-(3-(trifluoromethyl)indazol-6-yloxy)ethylamino)ethyl)phenyl)methanesulfonamide;
- and
- (R)-N-(3-(1-hydroxy-2-(2-(3-methoxyindazol-6-yloxy)ethylamino)ethyl)phenyl)benzenesulfonamide,
- or a salt thereof.
(R)-N-(3-(2-(2-(3-ethylindazol-6-yloxy)ethylamino)-1-hydroxyethyl)phenyl)methanesulfonamide or a salt thereof.
Dependencies are inferred from the claim text.